Most AI clinical reference tools are built for one market and one layer. UpToDate, OpenEvidence, and DynaMed are English-content reference engines built for US and UK practice; Glass Health and iatroX add reasoning and UK-guideline grounding. Meddies takes a different position: it is built to run inside the hospital EMR rather than as a separate web application, with a source on every answer. The differences are not cosmetic, and they decide whether a tool fits your patient.
This guide compares six AI clinical tools across the criteria that actually matter at the point of care — where the content comes from, whether you can verify every answer, whether the tool lives inside your EMR or in a separate tab, and how you pay for it. Every cell below is sourced to the vendor's own pages or an independent review; where a vendor does not state something publicly, the cell says so rather than guessing.
The shift that reset the category
Every major clinical reference platform now has a generative AI layer. As one industry review put it in March 2026, "Every major clinical reference platform now has a generative AI assistant... The era of keyword search in clinical reference is over" (iatroX, 2026). The underlying technology is broadly the same — retrieval-augmented generation, where the model answers from a retrieved corpus rather than from open-web memory — so the real differentiator is no longer "does it use AI." It is what the AI is allowed to read, whether you can check its work, and where it sits relative to your workflow.
That last point gets overlooked. A reference tool you open in a browser tab is a different product from an assistant that reads the chart you are already looking at, even when both answer the same clinical question. The comparison below treats workflow position as a first-class criterion, not a footnote.
What each tool actually is
UpToDate is the incumbent reference. Its content is authored by a network of physician editors — Wolters Kluwer puts the figure at over 7,600 clinicians — and its AI layer, UpToDate Expert AI, answers "grounded in the evidence-based recommendations" of that corpus, with inline links back to the supporting topic (Wolters Kluwer). It supports searching in 16 languages, but the clinical content itself "will remain in English" (Wolters Kluwer User Academy). Its AI-enhanced Enterprise Edition launched across APAC in September 2025 covering "Australia, New Zealand, Singapore, Taiwan and Hong Kong" — not Vietnam, Thailand, Indonesia, Malaysia, or the Philippines (Wolters Kluwer, Sept 8 2025).
OpenEvidence is the fast-growing disruptor. It draws answers from a large body of peer-reviewed literature — "35 million peer-reviewed medical publications" — and has content partnerships with the New England Journal of Medicine (February 2025) and JAMA (June 2025) (Contrary Research). It is free, by design: its own site states it uses cookies "to provide OpenEvidence to clinicians at no cost" (openevidence.com). But access is gated — it is "free to use for verified US healthcare professionals" who provide "a National Provider Identifier for access" (Contrary Research) — and it is geo-blocked in Europe: "OpenEvidence is not available in the European Union or the U.K." citing AI-regulation uncertainty (openevidence.com).
DynaMed, with its Dyna AI layer, is the evidence-graded reference. EBSCO states Dyna AI "sources information exclusively from our expert-curated, evidence-based content sets, DynaMedex, DynaMed or Dynamic Health" and provides "direct source links" (EBSCO Dyna AI). DynaMed builds content on a "rigorous, seven-step evidence-based methodology" and lists EHR integration as a workflow feature (EBSCO DynaMed). Access is mostly institutional, with US free trials: "Dyna AI free trials are available for US residents" (EBSCO Dyna AI).
Glass Health is the reasoning-and-scribing tool. It is an "AI-Powered Ambient Scribing & Clinical Decision Support" platform that listens to encounters, drafts a differential diagnosis, and answers clinical-reference questions "with evidence-based citations" shown inline as numbered references (glass.health). It is the only tool here besides DynaMed with documented EHR integration, available on its top tier "for Athena, Epic, eCW, Elation," and it runs a freemium model from a "Lite 0 USD / month" plan to a "Max From 180 USD / month" plan (Glass pricing).
iatroX is the UK-guideline-first tool, and a useful counterexample to the US-centric default. It uses "RAG over a curated library of UK-accepted guidelines and peer-reviewed research to deliver citation-first answers grounded in NICE, CKS, SIGN, BNF, and other trusted UK sources," it is "free for everyone... no professional verification," and it is "MHRA-registered (UKCA-marked Class I medical device)" — a level of UK regulatory assurance the international platforms do not claim (iatroX, 2026).
Meddies is the EMR-embedded layer built for Vietnam. It is designed as a clinical decision support system that runs inside the hospital EMR rather than as a separate web application, screening prescriptions for interactions and contraindications at the point of prescribing, producing chart summaries from the patient's record, and returning a source on every answer so the clinician can check the basis of a recommendation rather than take it on trust. The Meddies entries in the table below describe product design and positioning, not measured clinical outcomes — they are sourced to how the product is built, not to an efficacy study.
The comparison
| Criterion | UpToDate (+ Expert AI) | OpenEvidence | DynaMed (+ Dyna AI) | Glass Health | iatroX | Meddies |
|---|---|---|---|---|---|---|
| Content source | Expert-authored UpToDate corpus, 7,600+ clinicians [1] | 35M+ peer-reviewed papers; NEJM + JAMA partnerships [2] | Expert-curated DynaMed / DynaMedex / Dynamic Health only [3] | LLM agent over medical literature, cited inline [4] | UK guidelines: NICE, CKS, SIGN, BNF + research [5] | Not publicly stated |
| Source on every answer | Yes — inline links to supporting topic [1] | Yes — cited answers from literature [2] | Yes — direct source links + evidence grading [3] | Yes — numbered inline citations [4] | Yes — citation-first by design [5] | Yes — source travels with the recommendation, openable in one click (design) [6] |
| EMR-embedded vs separate app | Reference lookup; point-of-care, not EMR-native reasoning [5] | Standalone web + mobile app [2] | EHR integration listed as a feature [7] | EHR integration on Max tier (Epic, Athena, eCW, Elation) [8] | Standalone web + iOS/Android app [5] | Runs inside the hospital EMR by design [9] |
| Point-of-care vs reference layer | Reference layer (Expert AI adds reasoning) [1] | Reference / literature Q&A [2] | Reference + drug data [3] | Point-of-care reasoning + scribing [4] | Reference + reasoning [5] | Point-of-care: screens prescriptions and summarizes charts in-EMR (design) [9] |
| Pricing model | Individual / institutional paid subscription [10] | Free for verified US clinicians (NPI required) [2] | Institutional subscription; US free trials [3] | Freemium: $0 Lite → $180+/mo Max [8] | Free for everyone, no verification [5] | Not publicly stated |
| Market coverage (SEA) | APAC = AU/NZ/SG/TW/HK only [11] | US only; not available in EU/UK [12] | International (English) | International (English) | UK-first [5] | Built for Vietnam's EMR mandate (design) [9] |
The Meddies column describes product design and positioning; the other columns are sourced to the linked vendor pages and independent reviews. One figure circulating for UpToDate's individual US plan — roughly $530 per year — comes from a third-party review (iatroX, 2026); Wolters Kluwer's own page lists subscription options without a public individual price, so we report the model, not the number.
How to evaluate a clinical AI tool: the provenance test
The criteria above let you match a tool to your context, but they do not protect you from a fluent wrong answer. For that you need a verification habit, applied before you act on any AI-generated clinical recommendation. The most useful version of this — call it the provenance test — comes down to five questions, adapted from a 2026 clinical-AI review (iatroX).
Start with where the answer came from. A tool grounded in a curated, expert-reviewed corpus is more defensible for a clinical decision than one drawing from the open web, because someone took responsibility for what went in. Then ask whether you can verify the specific claim: does the tool give you a clickable citation to the actual source document, or just a confident paragraph? An answer you cannot trace is an answer you cannot stand behind. Check whether the source is current, since a superseded guideline cited confidently is worse than no citation. Ask whether the tool knows what it does not know — one that abstains when the evidence is thin is safer than one that always produces an answer. And in regulated markets, check whether the tool is registered as a medical device at all.
This is also why workflow position matters more than it looks. A tool that lives in a separate browser tab makes verification a deliberate act the clinician has to choose, between patients, under time pressure. A tool embedded in the EMR can put the source next to the recommendation, on the chart the doctor is already reading — which is the difference between asking a clinician to trust an answer and letting them verify one. As we have argued before, the source traveling with the recommendation is what turns trust into verification (Meddies).
Where this leaves a Vietnamese clinician
Run the provenance test against this list and the gap becomes concrete. UpToDate, OpenEvidence, and DynaMed are strong, well-sourced tools that pass the verification questions — for the markets and languages they were built for. Their content is English, and their footprint near Vietnam is thin: UpToDate's AI-enhanced edition reaches five APAC markets that do not include Vietnam (Wolters Kluwer), and OpenEvidence cannot even be opened from outside the US without verification (Contrary Research). Glass Health and iatroX show what point-of-care reasoning and local-guideline grounding look like done well — for the US and UK respectively.
None of that makes these tools inferior. It makes them foreign to one specific setting. Meddies is built for that setting: a clinical decision support layer that runs inside the hospital EMR that Circular 13/2025/TT-BYT is making compulsory across Vietnam — effective 21 July 2025, with hospitals required to adopt electronic medical records by 30 September 2025 and other facilities by 31 December 2026. The records are arriving on a fixed schedule. The intelligence built for them is the next question.